Chronic Idiopathic Urticaria Market is Projected to Grow at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – Novartis, Genentech, United BioPharma, GI Innovation

Chronic Idiopathic Urticaria Market is Projected to Grow at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies - Novartis, Genentech, United BioPharma, GI Innovation
Delveinsight Business Research LLP
As per DelveInsight, in the coming days, the competitive landscape for the Chronic spontaneous urticaria (CSU) market is set to transform due to improvements in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the launch of upcoming therapies.

DelveInsight’s “Chronic Idiopathic Urticaria Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chronic Idiopathic Urticaria market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Chronic Idiopathic Urticaria market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Idiopathic Urticaria Market

Chronic Idiopathic Urticaria: An Overview

Chronic spontaneous urticaria (CSU) or Chronic Idiopathic urticaria (CIU) is defined as persistent symptoms of urticaria for 6 weeks or more. It is a distressing skin condition that causes red, swollen, itchy, and sometimes painful hives or “wheals” on the skin. It is associated with autoimmunity in almost half of the cases, but the remaining cases still remain “idiopathic,” and all are considered spontaneous. Therefore, the term chronic spontaneous urticaria (CSU) has been employed to indicate chronic urticaria that is endogenous and independent of any external physical stimulus, which is conceptually helpful and does not imply knowing or not-knowing the cause.

Standard management of CSU primarily involves second-generation H1 antihistamines, often at higher than usual doses and in combination with H2 antihistamines and leukotriene modifiers. Chronic idiopathic urticaria (CIU) is the occurrence of close-to-daily wheals and pruritus for at least 6 weeks without an obvious cause.

Chronic Idiopathic Urticaria Market Key Facts

  • As per a study by Napolitano et al. (2020), the prevalence of Chronic urticaria (CU) in adults is estimated at 0.5% to 5%, while it affects 0.1% to 3% of children. Several studies showed that there was no difference in the prevalence of CSU between geriatric and adult patients.

  • According to Balp et al. (2017), almost 50% of patients had moderate-to-severe disease activity as reported by Urticaria Activity Score.

  • As per DelveInsight, extensive research and development activities of pharmaceutical companies, along with the expected launch of approved therapies, will fuel the market’s growth during the forecast period.

  • Globally, some of the major players in the Chronic Idiopathic Urticaria market in the late phase of clinical development are Novartis {(Ligelizumab), (LOU064)}, Genentech (Fenebrutinib), Sanofi and Regeneron (Dupilumab), and others.

Chronic Idiopathic Urticaria Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Chronic Idiopathic Urticaria market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Chronic Idiopathic Urticaria market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Chronic Idiopathic Urticaria Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Chronic Idiopathic Urticaria Epidemiology Segmentation by –

  • Total Prevalent cases of Chronic Idiopathic Urticaria

  • Gender-Specific cases of Chronic Idiopathic Urticaria

  • Age-specific cases of Chronic Idiopathic Urticaria

  • Total diagnosed and treatable prevalent cases of Chronic Idiopathic Urticaria

Chronic Idiopathic Urticaria Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Idiopathic Urticaria market or expected to get launched during the study period. The analysis covers the Chronic Idiopathic Urticaria market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Idiopathic Urticaria Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Chronic Idiopathic Urticaria Market Will Evolve by 2032 @

Chronic Idiopathic Urticaria Therapeutics Analysis

Antihistamines are the standard treatment for chronic idiopathic urticaria (CIU). The treatment options are limited for patients whose urticaria is unresponsive to antihistamines. During the previous decade, several case reports have demonstrated success with sulfasalazine therapy. To further improve the treatment scenario, certain key players are currently involved in developing therapies for Chronic Idiopathic Urticaria.

The key companies in the Chronic Idiopathic Urticaria Market include:

  • Novartis

  • Genentech

  • United BioPharma

  • GI Innovation

And many others.

Chronic Idiopathic Urticaria Therapies covered in the report include:

  • Ligelizumab

  • Fenebrutinib

  • UB 221

  • GI 301

And many more. 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Chronic Idiopathic Urticaria Competitive Intelligence Analysis

4. Chronic Idiopathic Urticaria Market Overview at a Glance

5. Chronic Idiopathic Urticaria Disease Background and Overview

6. Chronic Idiopathic Urticaria Patient Journey

7. Chronic Idiopathic Urticaria Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Chronic Idiopathic Urticaria Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Idiopathic Urticaria Unmet Needs

10. Key Endpoints of Chronic Idiopathic Urticaria Treatment

11. Chronic Idiopathic Urticaria Marketed Products

12. Chronic Idiopathic Urticaria Emerging Drugs and Latest Therapeutic Advances

13. Chronic Idiopathic Urticaria Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Idiopathic Urticaria Market Outlook (In US, EU5, and Japan)

16. Chronic Idiopathic Urticaria Access and Reimbursement Overview

17. KOL Views on the Chronic Idiopathic Urticaria Market

18. Chronic Idiopathic Urticaria Market Drivers

19. Chronic Idiopathic Urticaria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Chronic Idiopathic Urticaria (CIU) Pipeline Insights

“Chronic Idiopathic Urticaria Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Idiopathic Urticaria Market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States